Physician profile
Steven M Bromley
NPI 1962591586
$1,540,579.64
in general payments reported to CMS, 2019-2025
86 companies · $211K in 2025
The $211K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234K · 2020: $148K · 2021: $172K · 2022: $228K · 2023: $236K · 2024: $312K · 2025: $211K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $575K · Consulting Fee: $48K · Honoraria: $47K · Travel and Lodging: $40K · Food and Beverage: $35K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Education: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $575,350.50 |
| Consulting Fee | $48,169.31 |
| Honoraria | $47,260.00 |
| Travel and Lodging | $39,769.21 |
| Food and Beverage | $34,694.53 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,045.00 |
| Education | $223.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $191,710.25 | 2019-2025 | Mavenclad, Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $162,717.47 | 2020-2025 | Zeposia |
| Celgene Corporation | $124,236.30 | 2019-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $118,458.48 | 2019-2025 | Ultomiris |
| Abbvie INC. | $117,619.63 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Otsuka America Pharmaceutical, INC. | $109,714.66 | 2022-2025 | Nuedexta, Rexulti |
| Lundbeck LLC | $100,907.84 | 2020-2025 | Vyepti, Rexulti |
| Genentech USA, INC. | $84,236.29 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Biogen, INC. | $79,846.18 | 2019-2025 | Tysabri, Vumerity, Plegridy |
| Lilly USA, LLC | $69,373.26 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Ucb, INC. | $65,142.85 | 2019-2025 | Rystiggo, Zilbrysq, Briviact |
| Genzyme Corporation | $45,258.91 | 2019-2025 | |
| Tg Therapeutics, INC. | $42,913.22 | 2023-2024 | Briumvi |
| Allergan, INC. | $42,455.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $37,452.13 | 2019 |
Show all 86 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32,026.44 | 2019-2025 | Uplizna |
| Avanir Pharmaceuticals, INC. | $26,352.44 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $26,304.82 | 2020-2021 | |
| Eisai INC. | $16,207.63 | 2019-2025 | |
| Argenx US, INC. | $16,064.79 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Biohaven Pharmaceutical Holding Company Ltd. | $9,531.07 | 2022 | |
| Ani Pharmaceuticals, INC. | $7,691.06 | 2022-2025 | Purified Cortrophin Gel |
| Pfizer INC. | $4,555.28 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $742.94 | 2019-2025 | Austedo Xr, Austedo Xr |
| Amneal Pharmaceuticals LLC | $574.75 | 2019-2025 | Crexont, Rytary, Ongentys |
| Neurocrine Biosciences, INC. | $490.39 | 2020-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $438.75 | 2019-2025 | Nuplazid, Daybue |
| Mallinckrodt Hospital Products INC. | $417.70 | 2020-2025 | Acthar |
| Mdd US Operations, LLC | $417.32 | 2020-2025 | Gocovri |
| Axsome Therapeutics, INC. | $412.71 | 2022-2025 | Sunosi |
| Impel Pharmaceuticals INC. | $374.69 | 2022-2023 | Trudhesa |
| Takeda Pharmaceuticals U.S.A., INC. | $328.16 | 2020-2025 | Hyqvia, Trintellix, Gammagard |
| Kyowa Kirin, INC. | $322.98 | 2020-2025 | Nourianz |
| Scilex Pharmaceuticals INC. | $317.70 | 2023-2025 | Ztlido |
| Harmony Biosciences LLC | $272.11 | 2021-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $266.97 | 2020-2025 | Xywav |
| Janssen Pharmaceuticals, INC | $244.69 | 2020-2022 | |
| Averitas Pharma INC. | $214.17 | 2023-2025 | Qutenza |
| Sunovion Pharmaceuticals INC. | $210.64 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $195.74 | 2021-2025 | Xeomin, Ampyra, Inbrija |
| Upsher-Smith Laboratories LLC | $179.96 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $177.29 | 2019-2020 | |
| Boston Scientific Corporation | $176.32 | 2021-2025 | Ams 700, General - Dbs, Vercise |
| Sk Life Science, INC. | $168.39 | 2020-2022 | |
| Horizon Therapeutics Plc | $161.61 | 2020-2023 | Uplizna |
| Ge Healthcare | $157.16 | 2022-2025 | |
| Neuronetics, INC. | $152.28 | 2022-2023 | Neurostar Tms Therapy System |
| Arbor Pharmaceuticals, INC. | $136.13 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $121.77 | 2020-2025 | Ponvory, Hetlioz |
| Impel Pharmaceuticals LLC | $117.45 | 2025 | Trudhesa |
| Grt US Holding, INC. | $117.03 | 2021-2022 | |
| Neurelis, INC. | $115.55 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $113.53 | 2020-2021 | |
| Merz North America, INC. | $109.07 | 2019-2020 | |
| Csl Behring | $107.90 | 2019-2025 | Hizentra |
| Janssen Biotech, INC. | $104.52 | 2025 | |
| Abbott Laboratories | $89.22 | 2023-2024 | Infinity |
| Acorda Therapeutics, INC | $88.47 | 2019-2023 | Ampyra |
| Philips North America LLC | $87.47 | 2019-2020 | |
| Adlon Therapeutics L.P. | $80.56 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $77.49 | 2021-2023 | Belsomra |
| Astrazeneca Pharmaceuticals Lp | $72.32 | 2021-2024 | Evusheld |
| Life Molecular Imaging Ltd | $68.10 | 2024-2025 | Neuraceq |
| Almatica Pharma LLC | $66.56 | 2021-2023 | Gralise |
| Genentech, INC. | $60.05 | 2024-2025 | Ocrevus |
| Tris Pharma INC | $57.35 | 2023 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $54.49 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $53.90 | 2019 | |
| Azurity Pharmaceuticals, INC. | $49.05 | 2023 | Horizant |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.44 | 2022-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $46.57 | 2022-2024 | Quviviq |
| Ipsen Biopharmaceuticals, INC | $44.47 | 2022-2024 | Dysport |
| Tanabe Pharma America, INC. | $38.81 | 2019 | |
| Nevro Corp. | $38.18 | 2020-2023 | Senza |
| Corium, LLC | $30.16 | 2023-2024 | Azstarys |
| Banner Life Sciences, LLC | $29.02 | 2022 | |
| Grifols USA, LLC | $27.05 | 2021-2024 | Gamunex-C |
| Catalyst Pharmaceuticals, INC. | $17.50 | 2022 | |
| W. L. Gore & Associates, INC. | $17.10 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.33 | 2025 | Keveyis |
| Octapharma USA, INC. | $15.49 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $14.95 | 2025 | Lumryz |
| Avion Pharmaceuticals | $14.62 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.55 | 2023 | Belbuca |
| Strongbridge US INC. | $14.40 | 2020 | |
| Shire North American Group INC | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Bromley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.